Company
InxMed (Shanghai) Co., Ltd.
InxMed (Shanghai) Co., Ltd. has 5 drugs tracked on RxWires: 1 in Phase 3, 1 in Phase 2, 3 in Phase 1/2.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| IN10018 in combination with D-1553 | Phase 3 | Non-Small Cell Lung Cancer |
| IN10018 | Phase 2 | Ovarian Cancer Recurrent |
| IN10018 in combination with RNK08954 | Phase 1/2 | Solid Tumor Cancer |
| IN10018（Ifebemtinib） | Phase 1/2 | Solid Tumor |
| IN10018 in combination with PLD | Phase 1/2 | Platinum-resistant Ovarian Cancer |
Latest
No recent events.
Follow InxMed (Shanghai) Co., Ltd. on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.